TG Therapeutics (NASDAQ:TGTX) Trading Up 9.8% - Should You Buy?

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) was up 9.8% during mid-day trading on Wednesday . The company traded as high as $39.29 and last traded at $41.46. Approximately 499,481 shares traded hands during trading, a decline of 84% from the average daily volume of 3,064,185 shares. The stock had previously closed at $37.75.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on TGTX shares. HC Wainwright reissued a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, TG Therapeutics has an average rating of "Moderate Buy" and an average price target of $40.67.

TG Therapeutics Stock Down 5.1 %

The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The company has a market cap of $5.87 billion, a P/E ratio of -373.46 and a beta of 2.13. The stock has a 50-day moving average of $35.27 and a 200 day moving average of $30.85.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.08 by $0.07. The business had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. Research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Remove Ads

Insider Transactions at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now owns 660,611 shares of the company's stock, valued at $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 10.50% of the company's stock.

Institutional Investors Weigh In On TG Therapeutics

Several institutional investors have recently added to or reduced their stakes in TGTX. Arizona State Retirement System grew its position in shares of TG Therapeutics by 0.9% in the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after buying an additional 364 shares during the period. Blue Trust Inc. boosted its stake in TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 371 shares during the period. Summit Investment Advisors Inc. lifted its position in shares of TG Therapeutics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock worth $440,000 after buying an additional 463 shares in the last quarter. Brookstone Capital Management grew its stake in shares of TG Therapeutics by 3.7% in the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock worth $527,000 after buying an additional 624 shares in the last quarter. Finally, Daymark Wealth Partners LLC increased its position in shares of TG Therapeutics by 1.7% during the 4th quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock valued at $1,249,000 after purchasing an additional 689 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.